Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
Biodesix (NASDAQ:BDSX), a diagnostic solutions company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biodesix (NASDAQ:BDSX), a diagnostic solutions company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. CEO Scott Hutton and CFO Robin Cowie will engage in a fireside chat and conduct one-on-one investor meetings on August 12, 2025, at 4:30 PM ET in Boston, MA.
The presentation will be accessible via live webcast and available for replay in the Investors section of biodesix.com under "News & Events".
Details
News Market Reaction – BDSX
On Aug 5, the day this news came out, BDSX closed 10.10% above the previous close.
Data tracked by StockTitan Argus for the Aug 5 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025.
Canaccord Genuity 45th Annual Growth Conference
Fireside Chat Date: Tuesday, August 12, 2025
Fireside Chat Time: 4:30 PM ET
Location: Boston, MA
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Contacts:
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investors:
Chris Brinzey
Chris.Brinzey@icrhealthcare.com
1-339-970-2843
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.